Pay in 4 interest-free payments of $6.71 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
The Substances on the Table These are the drugs being reviewed and the medical uses FDA will be evaluating: July 23, 2026: BPC-157 (free base and acetate) ulcerative colitis KPV (free base and acetate) wound healing and inflammatory conditions TB-500 (free base and acetate) wound healing MOTs-C (free base and acetate) obesity and osteoporosis July 24, 2026: Emideltide / DSIP (delta sleep-inducing peptide, free base and acetate) opioid withdrawal, chronic insomnia, and narcolepsy Semax (free base and acetate) cerebral ischemia, migraine, and trigeminal neuralgia Epitalon (free base and acetate) insomnia If any or all of these substances are added to the 503A Bulks List following this process, it would formalize the legal pathway for licensed pharmacists and physicians to compound them for patients
Xiong, H., Callaghan, D., Jones, A., Bai, J., Rasquinha, I., Smith, C., Pei, K., Walker, D., Lue, L.-F., Stanimirovic, D., & Zhang, W
CMLS (2019)
For peptides for healing tendons and peptides for joint repair specifically, BPC-157 injected near the injury site is the most commonly referenced protocol in practitioner settings
For someone new to the beauty industry, that complexity can quickly become discouraging
